Clinical Trials Directory

Trials / Conditions / Epstein-Barr Virus Infection

Epstein-Barr Virus Infection

12 registered clinical trials studyying Epstein-Barr Virus Infection — 2 currently recruiting.

StatusTrialSponsorPhase
RecruitingExploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transpl
NCT07368634
Daihong LiuPhase 1 / Phase 2
RecruitingEpstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Ad
NCT06908096
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1
Active Not RecruitingTrial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vacc
NCT05683834
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1 / Phase 2
Active Not RecruitingA Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participant
NCT05831111
ModernaTX, Inc.Phase 1
Active Not RecruitingSafety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults
NCT04645147
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1
Active Not RecruitingA Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents
NCT05164094
ModernaTX, Inc.Phase 1 / Phase 2
CompletedMental Training for CFS Following EBV Infection in Adolescents
NCT02499302
University Hospital, AkershusN/A
Active Not RecruitingIndividualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NCT02135042
NRG OncologyPhase 2 / Phase 3
TerminatedBrentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
NCT01805037
Northwestern UniversityPhase 1 / Phase 2
Active Not RecruitingAdministration of Donor T Cells With the Caspase-9 Suicide Gene
NCT01494103
Baylor College of MedicinePhase 1
CompletedEffects of Long-Term Treatment With Valaciclovir (Valtrex) on Epstein-Barr Virus
NCT00005924
National Institute of Allergy and Infectious Diseases (NIAID)—
AvailableTETRAVI Expanded Access Program
NCT07104591
Baylor College of Medicine—